Uptrend. Merck’s Q3 earnings call revealed a profitable quarter with solid performance across key brand names and progress in pipeline projects. The recent launch of cancer treatment KEYTRUDA and its potential as a leading anti-PD1 therapy inject positive sentiment. The pipeline’s progress in hepatitis C treatments, Vaccines and合并氏 ministério additional upside. Cost-cutting measures contribute to margins, with a focus on sustainable growth maintaining investors’ confidence. expect the stock to rise in the short term.

2